68/100B63.425
USD
1.09
(1.75%)
Post Trading·63.490USD+0.065(+0.10%)
Last updated: · Delayed 15 min
Bristol-Myers Squibb financials
Yes. Bristol-Myers Squibb earned 9.24B USD of net income over the last twelve months, 18.5% of its revenue. It made a profit in 37 of its 39 fiscal years since 1987. Its last loss was in fiscal year 2024.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 50.03B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 9.24B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 9.29B USD
- Cash and short-term investments
- 12.58B USD
- Total debt
- 44.81B USD
- Shareholders' equityWhat is a balance sheet? The balance sheet lists what a company owns (assets), what it owes (liabilities) and what is left for its shareholders (equity) on one date.
- 23.40B USD
Cash, debt and equity as of 30 Sept 2026.
Bristol-Myers Squibb earnings
Next earnings · Q4 FY2026
EPS estimate
1.53 USD
Revenue estimate
12.66B USD
Last quarter · Q3 FY2026
EPS1.35Beat +22.7%Revenue13.07BBeat +2.7%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2028 | 1.37 | — | — | -10.25% | 10.62B | — | — | -6.23% | |
| Q4 FY2027 | 1.60 | — | — | +4.27% | 12.41B | — | — | -1.97% | |
| Q1 FY2027 | 1.52 | — | — | -3.69% | 11.33B | — | — | -1.39% | |
| Q4 FY2026 | 1.53 | — | — | +21.43% | 12.66B | — | — | +1.28% | |
| Q3 FY2026 | 1.10 | 1.35 | +22.73% | -17.18% | 12.72B | 13.07B | +2.72% | +6.93% | |
| Q2 FY2026 | 1.60 | 2.04 | +27.50% | +39.73% | 11.74B | 12.97B | +10.51% | +5.74% | |
| Q1 FY2026 | 1.42 | 1.58 | +11.27% | -12.22% | 10.93B | 11.49B | +5.14% | +2.57% | |
| Q4 FY2025 | 1.23 | 1.26 | +2.44% | -24.55% | 12.28B | 12.50B | +1.80% | +1.30% | |
| Q3 FY2025 | 1.52 | 1.63 | +7.24% | -9.44% | 11.85B | 12.22B | +3.14% | +2.77% | |
| Q2 FY2025 | 1.09 | 1.46 | +33.94% | -29.47% | 11.44B | 12.27B | +7.21% | +0.56% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 5.30 | — | — | -20.95% | 40.38B | — | — | -17.30% |
| FY2027 | 6.70 | — | — | +3.96% | 48.83B | — | — | -2.68% |
| FY2026 | 6.44 | — | — | +4.78% | 50.17B | — | — | +4.11% |
| FY2025 | 6.11 | 6.15 | +0.59% | +439.47% | 47.99B | 48.19B | +0.43% | -0.22% |
| FY2024 | 0.92 | 1.14 | +24.56% | -84.80% | 47.51B | 48.30B | +1.66% | +7.32% |
| FY2023 | 7.38 | 7.50 | +1.59% | -2.60% | 44.71B | 45.01B | +0.66% | -2.50% |
| FY2022 | 7.39 | 7.70 | +4.24% | +2.67% | 45.92B | 46.16B | +0.52% | -0.49% |
Bristol-Myers Squibb growth and profitability
Full income statement- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 50.03B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 9.24B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 69.24%
- Operating margin
- 26.07%
- Net margin
- 18.47%
Revenue / Net income
Revenue Net income Net margin
How Bristol-Myers Squibb makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Eliquis14.44B 30.0%
Opdivo10.05B 20.9%
Orencia3.71B 7.7%
Revlimid2.95B 6.1%
Yervoy2.90B 6.0%
Pomalyst/Imnovid2.73B 5.7%
Reblozyl2.33B 4.8%
Other Growth Brands1.92B 4.0%
Breyanzi1.36B 2.8%
Opdualag1.19B 2.5%
Camzyos1.07B 2.2%
Other Legacy Brands798.00M 1.7%
Zeposia577.00M 1.2%
Sprycel493.00M 1.0%
Abecma427.00M 0.9%
Abraxane368.00M 0.8%
Sotyktu291.00M 0.6%
Opdivo Ovantig238.00M 0.5%
Krazati205.00M 0.4%
Cobenfy155.00M 0.3%
Revenue48.20B 100.0%
Cost of revenue13.94B 28.9%
Gross profit34.26B 71.1%
Research and development9.95B 20.6%
Selling and administration7.27B 15.1%
Other operating expenses3.32B 6.9%
Operating income13.72B 28.5%
Tax2.27B 4.7%
Other expense4.40B 9.1%
Net income7.05B 14.6%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Bristol-Myers Squibb revenue breakdown
By product
FY2025
30.0%Eliquis20.9%Opdivo7.7%Orencia6.1%Revlimid6.0%Yervoy5.7%Pomalyst/Imnovid4.8%Reblozyl4.0%Other Growth Brands2.8%Breyanzi2.5%Opdualag2.2%Camzyos1.7%Other Legacy Brands1.2%Zeposia1.0%Sprycel
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Eliquis | 14.44B | 30.0% | +8.3% |
| Opdivo | 10.05B | 20.9% | +8.0% |
| Orencia | 3.71B | 7.7% | +0.6% |
| Revlimid | 2.95B | 6.1% | -48.9% |
| Yervoy | 2.90B | 6.0% | +14.6% |
| Pomalyst/Imnovid | 2.73B | 5.7% | -22.9% |
| Reblozyl | 2.33B | 4.8% | +31.2% |
| Other Growth Brands | 1.92B | 4.0% | +19.9% |
| Breyanzi | 1.36B | 2.8% | +81.8% |
| Opdualag | 1.19B | 2.5% | +27.7% |
| Camzyos | 1.07B | 2.2% | +77.4% |
| Other Legacy Brands | 798.00M | 1.7% | -13.7% |
| Zeposia | 577.00M | 1.2% | +1.9% |
| Sprycel | 493.00M | 1.0% | -61.7% |
| Abecma | 427.00M | 0.9% | +5.2% |
| Abraxane | 368.00M | 0.8% | -57.9% |
| Sotyktu | 291.00M | 0.6% | +18.3% |
| Opdivo Ovantig | 238.00M | 0.5% | — |
| Krazati | 205.00M | 0.4% | +62.7% |
| Cobenfy | 155.00M | 0.3% | +1,450.0% |
By region
FY2025
96.8%United States3.2%Other Region
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 33.28B | 96.8% | -2.4% |
| Other Region | 1.09B | 3.2% | +9.1% |
Operating and free cash flow
Full cash flow statementOperating cash flow Free cash flow
Bristol-Myers Squibb financial health
Full balance sheet- Cash and short-term investments
- 12.58B USD
- Total debt
- 44.81B USD
- Net cash
- -32.23B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 9.29B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 1.59
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 1.91
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 7 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 2.71
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Assets, liabilities and equity
Total assets Total liabilities Shareholders' equity
Bristol-Myers Squibb valuation
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 14.03
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 9.84
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 2.59
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 5.54
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 10.68
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
129.65B USD
+
Total debt
44.81B USD
−
Cash and short-term investments
12.58B USD
=
Enterprise value
161.88B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Bristol-Myers Squibb against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Pfizer, Gilead Sciences, Amgen, Merck & Co., Biogen, and AbbVie, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- Gross marginBelow its median71.1%71.1%78.6%Against its peers: 4 of 7Peers' median 71.4%
- Operating marginHighest in 5 years28.5%12.2%28.5%Against its peers: 5 of 7Peers' median 31.0%
- Net marginAt its median14.6%-18.5%17.8%Against its peers: 4 of 7Peers' median 17.1%
- Return on equityHighest in 5 years38.2%-54.8%38.2%Against its peers: 2 of 6Peers' median 34.7%
- Free cash flow marginBelow its median26.7%25.9%32.8%Against its peers: 3 of 7Peers' median 21.5%
- Revenue growthAt its median-0.2%-2.5%9.1%Against its peers: 6 of 7Peers' median 1.9%
- Debt to EBITDAAbove its median3.10×2.12×16.16×Against its peers: 4 of 7Peers' median 2.80×
- Current ratioAt its median1.261.251.52Against its peers: 4 of 7Peers' median 1.35
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Bristol-Myers Squibb dividends
- Annual dividend
- 2.52 USD
- Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 3.97%
- Payout ratioWhat is the payout ratio? The payout ratio is the share of a company's earnings paid out as dividends: dividends per share divided by earnings per share (EPS).
- 55.75%
- Years of dividend growthWhat are years of dividend growth? The years in a row a company has raised its dividend per share. 25 years make an S&P 500 company a Dividend Aristocrat; 50 make a Dividend King.
- 19
- Frequency
- Quarterly
- Last payment
- 0.63 USD
- Last ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.
- 2 Oct 2026
- Last payment date
- 2 Nov 2026
Dividends per share
Bristol-Myers Squibb ownership
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 85.41%
- Institutional holders
- 2,636 (-24)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 99.68%
Who owns the shares
Institutions 85.4% Others 14.6%
As of 30 Jun 2026
Shares free to trade
Free float 2.04B shares ·99.7% Closely held 6.47M shares ·0.3%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 1 | 28.01K | 45.19K |
| Q3 2026 | 0 | 2 | 56.59K | 87.57K |
| Q2 2026 | 0 | 2 | 36.56K | 69.55K |
| Q1 2026 | 0 | 0 | 1.17M | 404.23K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Common questions about Bristol-Myers Squibb's financials
Source: Financial Modeling PrepVerified against SEC filings